Mitigation of Fibrosis after Myocardial Infarction in Rats by Using a Porcine Cholecyst Extracellular Matrix.

IF 1.3 4区农林科学 Q2 VETERINARY SCIENCES

Comparative medicine Pub Date : 2023-08-27 Epub Date: 2023-08-01 DOI:10.30802/AALAS-CM-22-000097

Reshma S Nair, Praveen K Sobhan, Sachin J Shenoy, Mukund A Prabhu, Vikas Kumar, Surya Ramachandran, Thapasimuthu V Anilkumar

{"title":"Mitigation of Fibrosis after Myocardial Infarction in Rats by Using a Porcine Cholecyst Extracellular Matrix.","authors":"Reshma S Nair, Praveen K Sobhan, Sachin J Shenoy, Mukund A Prabhu, Vikas Kumar, Surya Ramachandran, Thapasimuthu V Anilkumar","doi":"10.30802/AALAS-CM-22-000097","DOIUrl":null,"url":null,"abstract":"<p><p>Fibrosis that occurs after nonfatal myocardial infarction (MI) is an irreversible reparative cardiac tissue remodeling process characterized by progressive deposition of highly cross-linked type I collagen. No currently available therapeutic strategy prevents or reverses MI-associated fibrotic scarring of myocardium. In this study, we used an epicardial graft prepared of porcine cholecystic extracellular matrix to treat experimental nonfatal MI in rats. Graft-assisted healing was characterized by reduced fibrosis, with scanty deposition of type I collagen. Histologically, the tissue response was associated with a favorable regenerative reaction predominated by CD4-positive helper T lymphocytes, enhanced angiogenesis, and infiltration of proliferating cells. These observations indicate that porcine cholecystic extracellular matrix delayed the fibrotic reaction and support its use as a potential biomaterial for mitigating fibrosis after MI. Delaying the progression of cardiac tissue remodeling may widen the therapeutic window for management of scarring after MI.</p>","PeriodicalId":10659,"journal":{"name":"Comparative medicine","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702285/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Comparative medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.30802/AALAS-CM-22-000097","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Fibrosis that occurs after nonfatal myocardial infarction (MI) is an irreversible reparative cardiac tissue remodeling process characterized by progressive deposition of highly cross-linked type I collagen. No currently available therapeutic strategy prevents or reverses MI-associated fibrotic scarring of myocardium. In this study, we used an epicardial graft prepared of porcine cholecystic extracellular matrix to treat experimental nonfatal MI in rats. Graft-assisted healing was characterized by reduced fibrosis, with scanty deposition of type I collagen. Histologically, the tissue response was associated with a favorable regenerative reaction predominated by CD4-positive helper T lymphocytes, enhanced angiogenesis, and infiltration of proliferating cells. These observations indicate that porcine cholecystic extracellular matrix delayed the fibrotic reaction and support its use as a potential biomaterial for mitigating fibrosis after MI. Delaying the progression of cardiac tissue remodeling may widen the therapeutic window for management of scarring after MI.

查看原文本刊更多论文

猪胆囊囊肿细胞外基质对大鼠心肌梗死后纤维化的缓解作用。

非致命性心肌梗死（MI）后发生的纤维化是一种不可逆的修复性心脏组织重塑过程，其特征是高度交联的I型胶原的逐渐沉积。目前没有可用的治疗策略可以预防或逆转心肌梗死相关的纤维化瘢痕形成。在本研究中，我们使用由猪胆囊细胞外基质制备的心外膜移植物治疗大鼠实验性非致命性心肌梗死。移植物辅助愈合的特点是纤维化减少，I型胶原沉积不足。组织学上，组织反应与以CD4阳性辅助T淋巴细胞为主的有利再生反应、血管生成增强和增殖细胞浸润有关。这些观察结果表明，猪胆囊细胞外基质延缓了纤维化反应，并支持其作为缓解MI后纤维化的潜在生物材料的应用。延缓心脏组织重塑的进展可能拓宽MI后瘢痕形成的治疗窗口。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Comparative medicine 医学-动物学

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Comparative Medicine (CM), an international journal of comparative and experimental medicine, is the leading English-language publication in the field and is ranked by the Science Citation Index in the upper third of all scientific journals. The mission of CM is to disseminate high-quality, peer-reviewed information that expands biomedical knowledge and promotes human and animal health through the study of laboratory animal disease, animal models of disease, and basic biologic mechanisms related to disease in people and animals.